Core Insights - Starbucks Corporation is set to release its fourth-quarter earnings results on October 29, with analysts expecting earnings of 55 cents per share, a decrease from 80 cents per share in the same period last year [1] - The consensus estimate for quarterly revenue is $9.35 billion, an increase from $9.07 billion a year earlier [1] Dividend Information - On October 1, Starbucks raised its quarterly cash dividend from 61 cents to 62 cents per share [2] - Following the dividend announcement, Starbucks shares fell by 2.1%, closing at $85.43 [2] Analyst Ratings - Mizuho analyst Nick Setyan initiated coverage with a Neutral rating and a price target of $84 [4] - Barclays analyst Jeffrey Bernstein maintained an Overweight rating but reduced the price target from $115 to $95 [4] - Wells Fargo analyst Zachary Fadem kept an Overweight rating and lowered the price target from $105 to $100 [4] - Citigroup analyst Jon Tower maintained a Neutral rating and cut the price target from $99 to $84 [4] - Baird analyst David Tarantino upgraded the stock from Neutral to Outperform and increased the price target from $100 to $115 [4]

Core Viewpoint - CMOC's net profit for 3Q25 increased by 19% QoQ to RMB5.6 billion, significantly exceeding forecasts by 62% due to higher copper sales volume and a lower effective tax rate [1] Financial Performance - The company's copper sales volume decreased by 1% QoQ to 197.7k tonnes, but this was still 32% above forecasts due to a deviation from last year's seasonal pattern [2] - The effective profit tax rate was recorded at 27.5%, which is 9.5 percentage points lower than anticipated [2] - Cobalt sales were still recorded despite an export ban in the DRC, and trading profit surged 3.2 times QoQ, contributing to the strong earnings performance [2] Production Metrics - Copper output grew by 4% QoQ, while cobalt output fell by 12% QoQ, with the company continuing cobalt production despite the export ban [3] Future Earnings Expectations - Earnings are expected to surge by 42% QoQ in 4Q25, driven by a projected 10% increase in average LME copper prices and a rise in cobalt sales volume due to a secured export quota of 6.5k tonnes, which is 35% higher than 3Q25 sales [4] - A one-time gain of RMB1.5 billion from the disposal of a subsidiary in Xinjiang is also anticipated [4] Capital Expenditure and Growth Plans - The company plans to commence construction of Phase 2 of the KFM Mine in the DRC, with a capital expenditure of US$1.08 billion, which is 27% above previous forecasts [5] - This project is expected to add new capacity of 100k tonnes per annum of copper, with completion anticipated in the first half of 2027, at least six months ahead of prior estimates [5] Valuation Adjustments - The DCF-based target price has been raised from HK$13.91 to HK$15.56, reflecting increased earnings forecasts, equating to a 14.8x core 2025E P/E ratio [5]

Core Insights - Ulta Beauty, Inc. has a market capitalization of $23.4 billion and is a prominent specialty beauty retailer in the U.S. and Mexico, offering a variety of branded and private label products across multiple categories [1] Financial Performance - Analysts expect Ulta Beauty to report an EPS of $4.45 for fiscal Q3 2025, reflecting a 13.4% decrease from $5.14 in the same quarter last year [2] - For fiscal 2025, the forecasted EPS is $24.33, down 4% from $25.34 in fiscal 2024, but is projected to rebound to $26.95 in fiscal 2026, representing a year-over-year growth of 10.8% [3] Stock Performance - Ulta Beauty's shares have increased by 36.8% over the past 52 weeks, outperforming the S&P 500 Index's gain of 18.1% and the Consumer Discretionary Select Sector SPDR Fund's return of 19.5% during the same period [4] Recent Developments - Following the Q2 2025 results announced on August 28, Ulta Beauty's shares fell by 7.1%. Despite a 9.3% increase in net sales to $2.79 billion and a 9.1% rise in EPS to $5.78, concerns arose due to a decline in operating margin to 12.4% and a 20.5% increase in inventory to $2.4 billion [5] Analyst Sentiment - The consensus among analysts regarding ULTA stock is cautiously optimistic, with a "Moderate Buy" rating. Out of 27 analysts, 13 recommend "Strong Buy," 2 suggest "Moderate Buy," 11 indicate "Hold," and 1 advises "Strong Sell." The average price target for Ulta Beauty is $589.48, indicating a potential upside of nearly 14% from current levels [6]

Seagate Technology Holdings plc (NASDAQ:STX) will release earnings results for its fiscal first quarter, after the closing bell on Tuesday, Oct. 28.Analysts expect the Singapore-based company to report quarterly earnings at $2.4 per share, up from $1.58 per share in the year-ago period. The consensus estimate for Seagate's quarterly revenue is $2.55 billion, compared to $2.17 billion a year earlier, according to data from Benzinga Pro.On July 29, Seagate reported better-than-expected fourth-quarter financia ...

Core Insights - BioMarin Pharmaceutical Inc reported weaker-than-expected earnings for Q3, with earnings of 12 cents per share, missing the analyst consensus estimate of 37 cents per share [1] - Quarterly sales were reported at $776.133 million, also missing the analyst consensus estimate of $780.629 million [1] Financial Guidance - The company lowered its FY2025 adjusted EPS guidance from $4.40-$4.55 to $3.50-$3.60, while raising its sales guidance from $3.125 billion-$3.200 billion to $3.150 billion-$3.200 billion [2] - The CEO highlighted over 20% revenue growth from PALYNZIQ and VOXZOGO as key contributors to the business units [2] Stock Performance - Following the earnings announcement, BioMarin Pharmaceutical shares gained 4.3%, reaching $54.95 [3] - Analysts adjusted their price targets for the stock after the earnings report [3] Analyst Ratings - Morgan Stanley maintained an Overweight rating but lowered the price target from $104 to $98 [5] - HC Wainwright & Co. maintained a Neutral rating and cut the price target from $60 to $55 [5] - Barclays also maintained an Overweight rating, lowering the price target from $86 to $80 [5]

Core Insights - The J. M. Smucker Company (SJM) is a leading consumer packaged goods company based in Orrville, Ohio, with a market cap of $11.2 billion, producing a variety of food and beverage products [1] Financial Performance - Analysts expect SJM to report a diluted profit of $1.78 per share for the fiscal second quarter of 2026, representing a 23.6% decline from $2.76 per share in the same quarter last year [2] - For the full fiscal year, SJM is projected to report an EPS of $9.13, down 9.8% from $10.12 in fiscal 2025, but is expected to rebound with a 9.5% increase to $10 in fiscal 2027 [3] Stock Performance - SJM stock has underperformed the S&P 500 Index, which gained 18.4% over the past 52 weeks, with SJM shares declining by 9.7% during the same period [4] - Following the Q1 results announcement, SJM shares closed down more than 4%, with adjusted EPS of $1.90 falling short of Wall Street's expectations of $1.95, and revenue of $2.11 billion missing forecasts of $2.13 billion [5] Analyst Ratings - The consensus opinion on SJM stock is moderately bullish, with a "Moderate Buy" rating overall; out of 18 analysts, five recommend a "Strong Buy," three suggest a "Moderate Buy," and ten give a "Hold" rating [6] - The average analyst price target for SJM is $119.19, indicating a potential upside of 13.8% from current levels [6]

UnitedHealth Group Incorporated (NYSE:UNH) will release earnings results for the third quarter, before the opening bell on Tuesday.Analysts expect the company to report quarterly earnings at $2.81 per share, down from $7.15 per share in the year-ago period. The consensus estimate for UnitedHealth Group’s quarterly revenue is $113.06 billion, compared to $100.82 billion a year earlier, according to data from Benzinga Pro.The company has missed analyst estimates for revenue in five straight quarters. Prior to ...

The pressure is on top companies to keep reporting earnings that beat Wall Street's forecasts—and failure to do so could be met with severe consequences. ...

Company Overview - TransDigm Group Incorporated (TDG) has a market cap of $74.1 billion and specializes in engineered aircraft components for both commercial and military aircraft [1] - The company was founded in 1993 and is headquartered in Cleveland, Ohio, focusing on proprietary parts such as control systems, pumps, valves, and cockpit instruments [1] Earnings Projections - For fiscal Q4 2025, analysts project an EPS of $9.62, reflecting a 4.7% increase from $9.19 in the same quarter last year [2] - For fiscal 2025, EPS is expected to be $34.49, an 8.7% rise from $31.74 in fiscal 2024, with further growth anticipated to $37.91 in fiscal 2026, representing a 9.9% annual increase [3] Stock Performance - Over the past 52 weeks, TDG stock has slightly declined, underperforming the S&P 500 Index's 16.2% return and the Industrial Select Sector SPDR Fund's 13.2% gain [4] - On October 15, shares dropped 4.4% after Morgan Stanley lowered its price target to $1,600 from $1,750, citing increased debt and interest expenses, but maintained an "Overweight" rating with a potential upside of 21.9% [5] Analyst Ratings - The consensus view on TransDigm stock is bullish, with a "Strong Buy" rating from 16 out of 22 analysts, while 6 analysts suggest a "Hold" rating [6] - The mean price target of $1,555.10 indicates a premium of 15.2% from current price levels [6]

Core Insights - Boston Scientific Corporation reported third-quarter revenues of $5.07 billion, exceeding the consensus estimate of $4.97 billion, with adjusted earnings of 75 cents, surpassing both the consensus of 71 cents and management guidance of 70-72 cents [1] - The company forecasts net sales growth of approximately 20% in 2025 on a reported basis and around 15.5% on an organic basis, raising previous guidance of 18%-19% and 12%-14% respectively [2] - Adjusted earnings guidance was increased from $2.95-$2.99 to $3.02-$3.04, compared to the consensus of $2.98, with fourth-quarter adjusted earnings expected to be between 77 cents-79 cents versus consensus of 76 cents [2] Stock Performance - Following the earnings announcement, Boston Scientific shares gained 0.6% to trade at $104.40 [3] - Analysts have adjusted their price targets for Boston Scientific, with Morgan Stanley raising it from $125 to $130 and Wells Fargo from $124 to $125, both maintaining an Overweight rating [5]